Details

Autor(en) / Beteiligte

• Viswanathan, Srinivas R.
• Ha, Gavin
• Hoff, Andreas M.
• Wala, Jeremiah A.
• Carrot-Zhang, Jian
• Whelan, Christopher W.
• Haradhvala, Nicholas J.
• Freeman, Samuel S.
• Reed, Sarah C.
• Rhoades, Justin
• Polak, Paz
• Cipicchio, Michelle
• Wankowicz, Stephanie A.
• Wong, Alicia
• Kamath, Tushar
• Zhang, Zhenwei
• Gydush, Gregory J.
• Rotem, Denisse
• Love, J. Christopher
• Getz, Gad
• Gabriel, Stacey
• Zhang, Cheng-Zhong
• Dehm, Scott M.
• Nelson, Peter S.
• Van Allen, Eliezer M.
• Choudhury, Atish D.
• Adalsteinsson, Viktor A.
• Beroukhim, Rameen
• Taplin, Mary-Ellen
• Meyerson, Matthew

Titel

Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing

Ist Teil von

• Cell, 2018-07, Vol.174 (2), p.433-447.e19

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2018

Quelle

MEDLINE

Beschreibungen/Notizen

• Nearly all prostate cancer deaths are from metastatic castration-resistant prostate cancer (mCRPC), but there have been few whole-genome sequencing (WGS) studies of this disease state. We performed linked-read WGS on 23 mCRPC biopsy specimens and analyzed cell-free DNA sequencing data from 86 patients with mCRPC. In addition to frequent rearrangements affecting known prostate cancer genes, we observed complex rearrangements of the AR locus in most cases. Unexpectedly, these rearrangements include highly recurrent tandem duplications involving an upstream enhancer of AR in 70%–87% of cases compared with <2% of primary prostate cancers. A subset of cases displayed AR or MYC enhancer duplication in the context of a genome-wide tandem duplicator phenotype associated with CDK12 inactivation. Our findings highlight the complex genomic structure of mCRPC, nominate alterations that may inform prostate cancer treatment, and suggest that additional recurrent events in the non-coding mCRPC genome remain to be discovered. [Display omitted] •Linked-read genome sequencing of mCRPC resolves haplotypes and rearrangements•CDK12 inactivation is associated with a global tandem duplication phenotype•A majority of cases have duplications of an enhancer of the androgen receptor•Progression on androgen pathway inhibitors is associated with gains in AR and AR enhancer Linked-read genome sequencing data from patients highlight that amplification of an enhancer upstream of the androgen receptor locus is a key feature of metastatic castration-resistant prostate cancer.